文献速递前列腺癌

MRI与全mount病理检测不良组织学前列腺癌

Detection and Localization of Unfavorable-histology Prostate Cancer Using MRI and Whole-mount Histopathology.
PubMed 文献 · Eur Urol Oncol · 2026-08-07

本研究评估PI-RADS与自动RSIrs评分对不良组织学前列腺癌(uhPC)的检测和定位价值。多中心1022例患者水平检测中,两者AUC无显著差异(p=0.13)。病灶水平103例中,联合应用对指数肿瘤敏感性93%,对所有uhPC肿瘤敏感性90%。

要点

  • PI-RADS与RSIrs对uhPC患者水平检测效能无显著差异
  • 联合PI-RADS和RSIrs可提高uhPC病灶定位敏感性
  • MRI对uhPC检测敏感性高,支持其识别侵袭性病变的价值

核心结论

  • MRI对检测uhPC显示高敏感性,强化了其识别生物学侵袭性疾病的价值。
  • PI-RADS和自动RSIrs可能可用于靶向活检和肿瘤聚焦治疗,如对侵袭性前列腺内病灶进行局灶放疗剂量递增。

研究设计与样本

  • 患者水平检测:多中心队列1022例,以活检为参考标准,比较PI-RADS与RSIrs检测uhPC的AUC。
  • 病灶水平定位:单独队列103例,以根治性前列腺切除全mount病理为参考标准,评估PI-RADS和RSIrs对指数肿瘤及所有uhPC肿瘤的敏感性。

主要发现

  • 患者水平检测uhPC的AUC在PI-RADS与RSIrs间无显著差异(p=0.13)。
  • 病灶水平(n=103)对指数肿瘤敏感性:PI-RADS 87%(95%CI 79-94),RSIrs 85%(95%CI 78-93),两者联合93%(95%CI 86-98)。
  • 对所有uhPC肿瘤敏感性:PI-RADS 81%(95%CI 73-90),RSIrs 86%(95%CI 78-93),两者联合90%(95%CI 82-97)。

临床怎么用

  • MRI可用于识别生物学侵袭性前列腺癌,支持靶向活检和肿瘤聚焦治疗决策。
  • 联合PI-RADS与RSIrs可能提高uhPC病灶定位敏感性,辅助局灶治疗规划。

局限性

  • 病灶水平分析仅纳入选择手术的患者,存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Detecting localized prostate cancer (PC) with metastatic potential-defined as unfavorable-histology PC (uhPC), comprising Grade Group (GG) ≥3 disease or GG 2 disease with cribriform/intraductal features-is critical for guiding appropriate intervention. We evaluated the utility of the Prostate Imaging Reporting and Data System (PI-RADS) and the automated Restriction Spectrum Imaging restriction score (RSIrs; a biophysics-based quantitative MRI biomarker) for uhPC detection and localization. METHODS: We evaluated patient-level detection of uhPC in a multicenter cohort with biopsy as the reference standard and lesion-level localization in a separate cohort with whole-mount histopathology (WMHP) from radical prostatectomy. The area under the receiver operating characteristic curve (AUC) was calculated to compare patient-level detection of uhPC using PI-RADS and RSIrs. PI-RADS and RSIrs were used to evaluate sensitivity for the most aggressive tumor within the prostate (index tumor) and for all uhPC tumors on WMHP. KEY FINDINGS AND LIMITATIONS: The AUC for patient-level detection of uhPC did not differ significantly between PI-RADS and RSIrs in 1022 patients from five centers (p = 0.13). At the lesion level (n = 103 patients), sensitivity for the index tumor was 87% (95% confidence intervals [CI], 79-94) for PI-RADS, 85% (95% CI, 78-93) for RSIrs, and 93% (95% CI, 86-98) for the two combined. For all uhPC tumors, sensitivity was 81% (95% CI, 73-90) for PI-RADS, 86% (95% CI, 78-93) for RSIrs, and 90% (95% CI, 82-97) for the two combined. A limitation of the lesion-level analyses was that only patients who opted for surgery could be included. CONCLUSIONS AND CLINICAL IMPLICATIONS: MRI showed high sensitivity for detecting uhPC, reinforcing its value for identifying biologically aggressive disease. Both PI-RADS and automated RSIrs may be useful for targeted biopsy and tumor-focused treatment, such as focal radiation dose escalation to aggressive intraprostatic lesions.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Rojo Domingo M, Dornisch A, Conlin CC, et al. Detection and Localization of Unfavorable-histology Prostate Cancer Using MRI and Whole-mount Histopathology. Eur Urol Oncol. 2026. PMID: 42567735. doi:10.1016/j.euo.2026.07.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。